Curiteva, a medical know-how firm, has efficiently handled greater than 5,000 ranges utilizing the Encourage Cervical implant, simply two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D printed trabecular PEEK implant.
“I’ve seen exceptional radiographic proof with the Encourage platform, together with seen bone progress inside the graft window and thru the implant inside simply 3 to six months. This offers clinicians with an unparalleled capability to evaluate therapeutic and progress reliably,” stated Chambliss Harrod, MD from The Backbone Middle of Louisiana.
“With this implant, I typically require little to no bracing and have considerably higher confidence in each fusion charges and affected person satisfaction throughout multilevel ACDF procedures,” stated John Johnson, MD from SportsMed Orthopedic Surgical procedure and Backbone Middle in Alabama.
“After utilizing Allograft for 30+ years, I’ve lastly discovered a viable alternative for bone. These Curiteva implants have the potential to revolutionize not solely backbone care but in addition a variety of different functions the place beforehand bone might need been used. This know-how has set a brand new normal in affected person care by its modern design and distinctive biomechanical and potential organic properties,” stated Mark N. Hadley, MD from the College of Alabama Division of Neurosurgery in Birmingham, Alabama.
Engineered with Curiteva’s proprietary and internally developed FFF 3D printers, Encourage implants function a totally interconnected and built-in porous construction traversing the complete implant. Mixed with its HAFUSE sub-micron nano-texturing, the Encourage implant promotes through-growth, making a superior organic surroundings for bone integration.
Curiteva plans a full industrial launch after a profitable alpha launch of the Encourage TLIF Anterior and Encourage TLIF Indirect implants later this month. Moreover, the corporate is about to roll out alpha launches for its ALIF portfolio, encompassing Monolithic, Thoracolumbar Plate, and Standalone implants later this 12 months.
“These achievements replicate the synergy of modern know-how, world-class manufacturing, vibrant partnerships, and scientific belief,” stated Chad Falciani, Founder and Chairman of the Board at Curiteva.
